Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
about
Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community-Dwelling PopulationDevelopment of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator).Novel biomarkers for heart failure.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Using ST2 in cardiovascular patients: a review.Natural history and therapy of AL cardiac amyloidosis.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Appropriate pathology ordering? Troponin testing within an Australian Emergency Department.Can Natriuretic Peptides be Used to Guide Therapy?Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure.Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.Clinical roles of soluble ST2 for the outcomes of cardiac valve operationsPredictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients.
P2860
Q37240346-B4DAFC32-70A5-4221-AEFE-7810F681D98AQ37484132-347A073B-5F72-4B96-B3FF-C5C173670810Q38131790-59A39319-69FA-4DEE-BAA0-D2F8472507A0Q38154222-D8AD57D5-4DEB-4CF6-8CCA-8512138A632CQ38258665-2277719E-EE02-43A2-81DB-B9A7A86B65D6Q38275212-94BCEC10-EAE0-45EF-9E06-313D12C734C5Q38370866-D3EA2EB7-8BCA-4E14-9534-2DBD597E7CE2Q38876279-D45B759E-A9C9-4794-B8DA-3B6992B99594Q38967512-79ACC562-0E38-48AA-B658-F4ECA93018F9Q41381124-6C3984D6-F9DE-422E-A82D-05DB56F309CEQ47673152-9A3E73DD-1DB8-4648-B9FF-616C55F67083Q55094584-79FACDBE-1D3A-449B-AA68-E2FFD8372317Q55286403-31C0FB14-016E-4415-ADE3-0B9DF88252F9
P2860
Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Combined use of the novel biom ...... on vs conventional assessment.
@en
Combined use of the novel biom ...... on vs conventional assessment.
@nl
type
label
Combined use of the novel biom ...... on vs conventional assessment.
@en
Combined use of the novel biom ...... on vs conventional assessment.
@nl
prefLabel
Combined use of the novel biom ...... on vs conventional assessment.
@en
Combined use of the novel biom ...... on vs conventional assessment.
@nl
P2093
P50
P1476
Combined use of the novel biom ...... ion vs conventional assessment
@en
P2093
Agustín Urrutia
Amparo Galán
Marta de Antonio
P304
P356
10.1016/J.MAYOCP.2012.09.016
P407
P577
2013-02-04T00:00:00Z